Evommune shares fall sharply after trial fails to meet primary endpoint
Source Summary
Evommune's stock declined significantly following the announcement that a clinical trial failed to achieve its primary endpoint. The trial result represents a setback for the company's development program.
Why it matters
Failed clinical trial endpoints directly impact a biotech company's ability to advance drug candidates and generate future revenue.
